Page 1

Jazz Pharmaceuticals Exhibit 99.1 JAZZ PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND RAISES FULL YEAR EARNINGS GUIDANCE DUBLIN , November 9 , 2021 -- Jazz Pharmaceuticals plc ( Nasdaq : JAZZ ) today announced financial results for the third quarter of 2021 and updated financial guidance for 2021 . " Last year , we set the ambitious corporate objective of completing five key commercial launches through 2020 and 2021. With the launch of Xyway for idiopathic hypersomnia earlier this month , we have now accomplished this goal , demonstrating our significant execution capabilities and commitment to bring important new medicines forward for patients , " said Bruce Cozadd , chairman and chief executive officer of Jazz Pharmaceuticals . " The successful integration of GW underscores our ability to deliver on transformative M & A to grow our business . While there's more work to be done , I'm confident we have the right strategy , teams and capabilities in place to realize the blockbuster potential of Epidiolex and to discover , develop and launch additional novel , innovative medicines leveraging cannabinoid science . Our commercial execution , productive R & D engine and culture of commitment to patients and their families provide a strong foundation for significant and sustained growth . " Renée Galá , executive vice president and chief financial officer , added , “ This is an exciting time of transformation for Jazz , underpinned by operational execution , financial discipline and strategic capital allocation across our business . We continue to deliver on our business and financial targets which has enabled us to rapidly reduce our net leverage ratio to 4.41 times in just five months following the close of the GW transaction . We have also delivered on revenue growth and diversification . Recently launched or acquired products now make up over 50 % of net product sales , and we remain on track to meet our goal of at least 65 % in 2022. In addition , our prior investments in corporate development are translating into near - term catalysts as we advance JZP385 , JZP150 and Zepzelca into important new clinical trials . We will continue to prioritize disciplined capital allocation to assets and activities that drive growth and value , while remaining focused on achieving our net leverage ratio target of less than 3.5¹ times by the end of next year . " Key Highlights • • • • • • Total revenues increased 39 % to $ 838.1 million compared to 3Q20 52 % of net product sales from recently launched or acquired products Exceptional XywavⓇ adoption in narcolepsy with approximately 6,000 active patients exiting 3Q21 Xywav for idiopathic hypersomnia ( IH ) launched November 1 , 2021 Continued Epidiolex® revenue growth of 21 % compared to 3Q20 despite COVID - 19 pressure Top - tier launch has established ZepzelcaⓇ as second - line SCLC treatment of choice Rylaze ™ launch progressing well ; positive feedback from key stakeholders Pipeline advancing with key trial initiations underway for JZP385 , JZP150 and Zepzelca Raising full year 2021 earnings guidance Net leverage ratio reduced by 0.5x to 4.4x¹ in the five months following GW transaction close 1 . On a pro forma , non - GAAP adjusted basis 1